Bristol Myers Squibb (NYSE: BMY) is scheduled to report its This autumn 2020 outcomes on Thursday, February 4. We anticipate the corporate to doubtless submit income and earnings barely beneath the consensus estimates, partly resulting from slowing gross sales development price of Opdivo. That mentioned, Bristol Myers Sq www.nasdaq.com
Bristol Myers Squibb (NYSE: BMY) is scheduled to report its This autumn 2020 outcomes on Thursday, February 4. We anticipate the corporate to doubtless submit income and earnings barely beneath the consensus estimates, partly resulting from slowing gross sales development price of Opdivo. That mentioned, Bristol Myers Sq
www.nasdaq.com